IPDA for High-Priority HIV-1 Subtypes to Enable Global Eradication Trials

NIH RePORTER · NIH · N43 · $299,975 · view on reporter.nih.gov ↗

Abstract

Sequence-based Assays to Quantify the Replication-Competent HIV Reservoir: Despite effective antiretroviral therapy (ART), HIV-1 persists in all infected individuals as proviral DNA within long-lived memory CD4+ T cells. This replication-competent HIV reservoir constitutes the primary barrier for curing HIV infection. The overall goal of this program is to develop and commercialize sequence-based HIV reservoir assays for clinical HIV cure interventions. Specifically, the assay should be designed as an analytical tool to monitor the size of the replication-competent HIV reservoir in clinical research and if successful, in prospective clinical trials.

Key facts

NIH application ID
10215310
Project number
75N93020C00015-0-9999-1
Recipient
ACCELEVIR DIAGNOSTICS, LLC
Principal Investigator
GREGORY LAIRD
Activity code
N43
Funding institute
NIH
Fiscal year
2020
Award amount
$299,975
Award type
Project period
2020-06-01 → 2021-05-31